Drug Trial Radar · NCT07486713
Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies
Last checked: Nov 20, 2026Latest source record: Aug 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
16
Planned (sponsor's estimate)
Start
Feb 23, 2026
Primary completion
Apr 30, 2027
Study completion Jun 30, 2027
Sponsor
- Lead sponsor
- Rigel PharmaceuticalsIndustry
- Sponsor type
- Industry
- First posted
- Mar 20, 2026
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Other
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A open-label drug-drug interaction (DDI) study to evaluate the effects of olutasidenib on the pharmacokinetics (PK) of a CYP450 and OATP1B1 probe substrate cocktail in participants with IDH1 mutation-positive malignancies.
Conditions
- AML (Acute Myeloid Leukemia)
- Glioma
- Cholangiocarcinoma
- Solid Tumor Malignancies
Interventions
OlutasidenibDrug
Participants will receive repeated dosing of olutasidenib from Day 5 to Day 22 until steady state, with an option to continue treatment up to Day 64
CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP3A4, and OATP1B1 Probe SubstratesDrug
Participants will receive a single dose of each probe substrate on Day 1 and Day 18.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Area Under the Plasma Concentration-Time Curve (AUC) of Probe DrugsTime frame: Up to 96 hours after each probe drug administration.
- Maximum Plasma Concentration (Cmax) of Probe DrugsTime frame: Up to 96 hours after each probe drug administration.
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
UCI Irvine Health
Orange, California · Recruiting
New York Presbyterian Hospital-Columbia University Medical Center
New York, New York · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.